SGMOQ SANGAMO THERAPEUTICS, INC
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1001233 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-31.6%
TTM net income YoY-25.5%
TTM EPS YoY10.2%
Revenue 3-yr CAGR-29.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-306.5%
Net margin-310.8%
FCF margin-246.0%
EBITDA margin-296.5%
Returns
ROE-2,891.8%
ROA-152.4%
ROIC (approx.)—
Asset turnover0.49x
Leverage & solvency
Liabilities / assets123.9%
Debt / equity—
Current ratio0.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-31.9%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $39.55M | $57.80M |
| R&D expense | $112.67M | $111.52M |
| SG&A expense | $34.89M | $44.73M |
| Operating income | -$121.24M | -$103.97M |
| Pretax income | -$123.50M | -$98.11M |
| Income tax | -$568,000 | -$167,000 |
| Net income | -$122.93M | -$97.94M |
| EBITDA | -$117.28M | -$98.86M |
| EPS (basic) | -0.44 | -0.49 |
| EPS (diluted) | -0.44 | -0.49 |
| Weighted avg. shares (diluted) | 280.19M | 201.70M |
| Balance sheet | ||
| Cash & equivalents | $20.95M | $41.92M |
| Receivables | $371,000 | $526,000 |
| Current assets | $35.83M | $51.69M |
| PP&E, net | $11.04M | $17.89M |
| Goodwill | — | $0 |
| Intangibles | — | $0 |
| Total assets | $59.74M | $101.64M |
| Current liabilities | $42.47M | $45.80M |
| Total liabilities | $74.01M | $78.86M |
| Shareholders' equity | -$14.27M | $22.77M |
| Shares outstanding | 350.69M | 212.84M |
| Cash flow statement | ||
| Operating cash flow | -$97.21M | -$67.14M |
| Capital expenditure | $102,000 | $267,000 |
| Free cash flow | -$97.31M | -$67.41M |
| Investing cash flow | -$102,000 | $37.52M |
| Financing cash flow | $70.75M | $28.38M |
| Depreciation & amortization | $3.96M | $5.11M |
| Stock-based compensation | $9.08M | $12.38M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.